Drug name - Glyxambi

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7407955 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
May, 2025

(2 years from now)

US7713938 BOEHRINGER INGELHEIM Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
Apr, 2027

(4 years from now)

US7579449 BOEHRINGER INGELHEIM Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
Aug, 2028

(5 years from now)

CN1930141A BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof
May, 2014

(8 years ago)

CN103450129A BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof
May, 2021

(1 year, 4 months ago)

CN103450129B BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof
May, 2021

(1 year, 4 months ago)

CN103435581B BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Phenyl Derivatives, Medicaments Containing Said Compounds, Use Thereof, And Method For Manufacturing The Same
Sep, 2021

(1 year, 20 days ago)

CN103467423B BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof
Sep, 2021

(1 year, 20 days ago)

CN103435581A BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof
Sep, 2021

(1 year, 20 days ago)

CN103467423A BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof
Sep, 2021

(1 year, 20 days ago)

CN101503408B BOEHRINGER INGELHEIM 8 - (3 - - Piperidine-1 - - Yl] - Xanthine Compounds
Aug, 2023

(10 months from now)

CN1675212A BOEHRINGER INGELHEIM 8 - (3-Amino-Piperidin-1-Yl] - Xanthine, Its Preparation Method And Its Purpose As A Pharmaceutical Preparation
Aug, 2023

(10 months from now)

CN105001222B BOEHRINGER INGELHEIM 8 - (3-Amino-Piperidin-1-Yl] - Xanthine, Its Preparation Method And Purpose As Medicine Preparation
Aug, 2023

(10 months from now)

CN100522962C BOEHRINGER INGELHEIM 8 - [3-Amino-Piperidin-1-Yl] - Xanthine, Its Preparation Method And Purpose As Medicine Preparation
Aug, 2023

(10 months from now)

CN101503408A BOEHRINGER INGELHEIM 8-(3-Amino-Piperidin-1-Yl)-Xanthines Compound
Aug, 2023

(10 months from now)

CN101503409A BOEHRINGER INGELHEIM 8-(3-Amino-Piperidin-1-Yl)-Xanthines, The Production Thereof And The Use Of The Same As Medicaments
Aug, 2023

(10 months from now)

CN102964347B BOEHRINGER INGELHEIM 8-[3-Amino-Piperidin-1-Yl]-Xanthines, Preparation Method Thereof And Application Thereof As Medicament
Aug, 2023

(10 months from now)

CN102964347A BOEHRINGER INGELHEIM 8 - (3 - - Piperidine-1 - - Yl] - Xanthine Compound, Preparation Method And Use Thereof As Pharmaceutical Preparation
Aug, 2023

(10 months from now)

CN101503409B BOEHRINGER INGELHEIM 8 - [3-Amino-Piperidin-L-Yl] - Xanthines, Processes For Their Preparation And Their Use As Pharmaceutical Preparations
Aug, 2023

(10 months from now)

CN105001222A BOEHRINGER INGELHEIM 8-[3-Amino-Piperidin-1-Yl]-Xanthines, Preparation Method Thereof And Application Thereof As Medicament
Aug, 2023

(10 months from now)

CN101155794B BOEHRINGER INGELHEIM 1 - -4-[Beta] -D - Glucopyranose - -1) -2-[4 - ((S) - Tetrahydrofuran - -3 - Yloxy) - Benzyl] - Crystal Form Of Benzene, Preparation Method Thereof And Use For Preparing Medicine
May, 2026

(3 years from now)

CN101155794A BOEHRINGER INGELHEIM Crystalline Form Of 1-Chloro-4-(Betal-D-Glucopyranos-1-Radical)-2-[4-((S)-Tetrahydrofuran-3-Yloxy)-Benzyl]-Benzene, A Method For Its Preparation And The Use Thereof For Preparing Medicaments
May, 2026

(3 years from now)

IN200500567P1 BOEHRINGER INGELHEIM 8-(3-Aminopiperidin-1-Yl)-Xanthine Compounds
Aug, 2023

(10 months from now)

IN243301B BOEHRINGER INGELHEIM 8-(3-Aminopiperidin-1-Yl)-Xanthine Compounds
Aug, 2023

(10 months from now)

IN200604844P1 BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof
Mar, 2025

(2 years from now)

IN268846B BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Benzenol Derivative, Drug Containing Said Compound, The Use Thereof And Method For The Production Thereof
Mar, 2025

(2 years from now)

EP1828216B1 BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Benzene Derivatives, Medicaments Containing Such Compounds, Their Use And Process For Their Manufacture
Dec, 2025

(3 years from now)

EP1828216A2 BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Benzene Derivatives, Medicaments Containing Such Compounds, Their Use And Process For Their Manufacture
Dec, 2025

(3 years from now)

EP1888552A1 BOEHRINGER INGELHEIM Crystalline Form Of 1-Chloro-4-(ß-D-Glucopyranos-1-Yl)-2-[4-((S)-Tetrahydrofuran-3-Yloxy)-Benzyl]-Benzene, A Method For Its Preparation And The Use Thereof For Preparing Medicaments
May, 2026

(3 years from now)

EP1888552B1 BOEHRINGER INGELHEIM Crystalline Form Of 1-Chloro-4-(ß-D-Glucopyranos-1-Yl)-2-[4-((S)-Tetrahydrofuran-3-Yloxy)-Benzyl]-Benzene, A Method For Its Preparation And The Use Thereof For Preparing Medicaments
May, 2026

(3 years from now)

EP1532149B9 BOEHRINGER INGELHEIM 8-[3-Amino-Piperidin-1-Yl]-Xanthines, The Production Thereof And The Use Of The Same As Medicaments
Aug, 2026

(3 years from now)

EP1532149A2 BOEHRINGER INGELHEIM 8-[3-Amino-Piperidin-1-Yl]-Xanthines, The Production Thereof And The Use Of The Same As Medicaments
Aug, 2026

(3 years from now)

EP1532149B1 BOEHRINGER INGELHEIM 8-[3-Amino-Piperidin-1-Yl]-Xanthines, The Production Thereof And The Use Of The Same As Medicaments
Aug, 2026

(3 years from now)

EP1730131B1 BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof
May, 2029

(6 years from now)

EP1730131A1 BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof
May, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8119648 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions Aug, 2023

(10 months from now)

US8178541 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions Aug, 2023

(10 months from now)

US8883805 BOEHRINGER INGELHEIM Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines Nov, 2025

(3 years from now)

US8673927 BOEHRINGER INGELHEIM Uses of DPP-IV inhibitors May, 2027

(4 years from now)

US9173859 BOEHRINGER INGELHEIM Uses of DPP IV inhibitors May, 2027

(4 years from now)

US11033552 BOEHRINGER INGELHEIM DPP IV inhibitor formulations May, 2027

(4 years from now)

US8551957 BOEHRINGER INGELHEIM Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate Oct, 2029

(7 years from now)

US10258637 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof Apr, 2034

(11 years from now)

US11090323 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof Apr, 2034

(11 years from now)

US9949998 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof Jun, 2034

(11 years from now)

Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN ingredient

Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin; Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin (with or without insulin or a sulfonylurea); method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin (with or without metformin); Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin and metformin; Method of treating type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin; Method of treating type 2 diabetes mellitus in a patient with renal impairment (30 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
10MG;5MG TABLET;ORAL Prescription
25MG;5MG TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.